RJA
EW icon

Raymond James & Associates’s Edwards Lifesciences EW Stock Holding History

Raymond James & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$111M Sell
1,675,733
-149,497
-8% -$10.9M 0.07% 247
2024
Q2 		$169M Buy
1,825,230
+50,124
+3% +$4.44M 0.11% 160
2024
Q1 		$170M Buy
1,775,106
+139,515
+9% +$11.7M 0.12% 163
2023
Q4 		$125M Sell
1,635,591
-23,062
-1% -$1.6M 0.09% 192
2023
Q3 		$115M Buy
1,658,653
+62,938
+4% +$5.06M 0.1% 184
2023
Q2 		$151M Buy
1,595,715
+128,746
+9% +$11.2M 0.12% 156
2023
Q1 		$121M Buy
1,466,969
+17,296
+1% +$1.36M 0.11% 177
2022
Q4 		$108M Sell
1,449,673
-153,510
-10% -$11.8M 0.1% 187
2022
Q3 		$132M Sell
1,603,183
-52,880
-3% -$5.09M 0.13% 143
2022
Q2 		$157M Buy
1,656,063
+9,341
+0.6% +$967K 0.15% 120
2022
Q1 		$194M Buy
1,646,722
+36,348
+2% +$4.08M 0.16% 114
2021
Q4 		$209M Buy
1,610,374
+139,703
+9% +$16.3M 0.17% 109
2021
Q3 		$166M Buy
1,470,671
+42,404
+3% +$4.84M 0.15% 127
2021
Q2 		$148M Buy
1,428,267
+318,774
+29% +$30M 0.13% 141
2021
Q1 		$92.8M Buy
1,109,493
+54,498
+5% +$4.61M 0.09% 184
2020
Q4 		$96.2M Buy
1,054,995
+181,235
+21% +$15M 0.11% 167
2020
Q3 		$69.7M Buy
873,760
+513,952
+143% +$40.1M 0.09% 189
2020
Q2 		$24.9M Buy
359,808
+15,636
+5% +$1.11M 0.03% 444
2020
Q1 		$21.6M Sell
344,172
-116,517
-25% -$8.4M 0.03% 434
2019
Q4 		$35.8M Buy
460,689
+1,851
+0.4% +$145K 0.05% 360
2019
Q3 		$33.6M Buy
458,838
+57,831
+14% +$4.06M 0.05% 359
2019
Q2 		$24.7M Buy
401,007
+7,764
+2% +$469K 0.04% 472
2019
Q1 		$25.1M Sell
393,243
-33,399
-8% -$1.91M 0.04% 448
2018
Q4 		$21.8M Buy
426,642
+5,289
+1% +$268K 0.04% 443
2018
Q3 		$24.5M Buy
421,353
+12,030
+3% +$588K 0.04% 457
2018
Q2 		$19.9M Sell
409,323
-43,158
-10% -$2.01M 0.03% 508
2018
Q1 		$21M Sell
452,481
-36,576
-7% -$1.59M 0.04% 452
2017
Q4 		$18.4M Sell
489,057
-4,221
-0.9% -$155K 0.03% 503
2017
Q3 		$18M Buy
493,278
+7,035
+1% +$268K 0.04% 496
2017
Q2 		$19.2M Buy
486,243
+61,878
+15% +$2.26M 0.04% 444
2017
Q1 		$13.3M Sell
424,365
-237,654
-36% -$7.44M 0.03% 548
2016
Q4 		$20.7M Sell
662,019
-88,548
-12% -$2.87M 0.05% 353
2016
Q3 		$30.2M Buy
750,567
+199,848
+36% +$7.53M 0.08% 239
2016
Q2 		$18.3M Sell
550,719
-5,211
-0.9% -$178K 0.06% 341
2016
Q1 		$16.3M Buy
555,930
+76,773
+16% +$2.12M 0.06% 365
2015
Q4 		$12.6M Buy
479,157
+29,601
+7% +$769K 0.05% 441
2015
Q3 		$10.7M Buy
449,556
+299,994
+201% +$7.24M 0.04% 461
2015
Q2 		$3.55M Sell
149,562
-22,104
-13% -$499K 0.01% 995
2015
Q1 		$4.08M Sell
171,666
-16,998
-9% -$381K 0.02% 854
2014
Q4 		$4M Buy
188,664
+618
+0.3% +$12.4K 0.02% 783
2014
Q3 		$3.2M Sell
188,046
-11,148
-6% -$176K 0.02% 843
2014
Q2 		$2.85M Buy
199,194
+27,156
+16% +$368K 0.02% 904
2014
Q1 		$2.13M Sell
172,038
-13,218
-7% -$153K 0.01% 1001
2013
Q4 		$2.03M Buy
+185,256
New +$2.09M 0.02% 947

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Raymond James & Associates's EW Position: Q3 2024 in Review

Raymond James & Associates reduced its Edwards Lifesciences (EW) stake by 8.2% in Q3 2024, selling an estimated $10.9M and leaving 1,675,733 shares worth $111M. The position accounts for 0.07% of the portfolio, ranked #247.

Raymond James & Associates first reported a position in EW in Q4 2013 and has held it in 44 quarters since. The position peaked at $209M in Q4 2021. 1,194 funds tracked by Wall St. Rank hold EW as of Q3 2024.

  • Raymond James & Associates held 1,675,733 shares of Edwards Lifesciences worth $111M as of Q3 2024.
  • Raymond James & Associates sold 149,497 Edwards Lifesciences shares in Q3 2024, an estimated $10.9M.
  • Edwards Lifesciences made up 0.07% of Raymond James & Associates's portfolio in Q3 2024, its #247 holding.
  • Raymond James & Associates first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 44 quarters since.
  • Raymond James & Associates's Edwards Lifesciences position peaked at $209M in Q4 2021.
  • 1,194 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.